FDA Greenlights First Bi-Monthly Injectable for Schizophrenia, Bipolar 1 Disorder
Otsuka and Lundbeck won approval Friday for Abilify Asimtufii, a long-acting injectable that provides two months of symptom relief in patients with schizophrenia or bipolar I disorder.
FDA Greenlights First Bi-Monthly Injectable for Schizophrenia, Bipolar 1 Disorder Read More »
